[Federal Register Volume 72, Number 67 (Monday, April 9, 2007)]
[Notices]
[Page 17583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-1723]



[[Page 17583]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--International Serum Industry Association

    Notice is hereby given that, on February 20, 2007, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), International Serum 
Industry Association (``ISIA'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing (1) the name and principal place of business of 
the standards development organization and (2) the nature and scope of 
its standards development activities. The notifications were filed for 
the purpose of invoking the Act's provisions limiting the recovery of 
antitrust plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the name and principal place 
of business of the standards development organization is: International 
Serum Industry Association, McHenry, MD. The nature and scope of ISIA's 
standards development activities are: to bring together, as members of 
the corporation, companies worldwide that are involved in the 
collection, sale, distribution, and processing of serum, and related 
companies. Serum is used in connection with research, diagnostic 
testing, and the development, sale and distribution of life sciences 
and biopharmaceutical products. The corporation's purpose is to enhance 
the understanding, safety, use and general knowledge of serum and serum 
related products by adopting, promoting and encouraging policies by 
which its members will: (1) Establish common nomenclature and testing 
standards for use within the serum industry; (2) work together to 
address common regulatory issues (e.g. import/export); (3) address 
common concerns about health related issues; (4) develop industry 
quality standards for product and company performance; (5) develop a 
market wide understanding of sourcing and traceability and policies to 
standardize business practices; (6) develop a proactive industry, 
regulatory and world interface to educate, inform and advocate as 
appropriate, acting as a spokesperson for the international serum 
industry in North America and other parts of the world on government 
and public policy issues, especially those impacting worldwide trade; 
(7) develop and implement standards of compliance to ensure that the 
industry is seen by all constituencies as operating at a high level of 
professional ethics; and (8) conduct such other activities, and adopt 
such other policies and practices, which are furtherance of the general 
objective of promoting uniform standards and reliability in the serum 
industry.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. 07-1723 Filed 4-6-07; 8:45 am]
BILLING CODE 4410-11-M